血清BNP浓度变化监测对预测STEMI患者PCI术后预后的预测价值

目的:分析血清B型钠尿肽(BNP)浓度变化对急性ST段抬高型心肌梗死(STEMI)患者经皮冠状动脉介入(PCI)术后预后的预测价值。方法:选取130例发病12 h内行PCI治疗的STEMI患者,通过荧光免疫法测定所有患者治疗前、发病24h、发病1周血清BNP水平,根据发病24 h血清BNP水平将患者分为A(≤100 pg/m L)、B(100~400 pg/m L)、C(400 pg/m L)三组,比较各组入院时Gensini评分、PCI术后1周左室射血分数(LVEF)、左心室舒张末期容积(LVEDV)、左心室壁运动积分指数(LVWMSI)及术后6个月预后(主要心血管不良事件)情况。结果:A组Gensini评分最低,B组居中,C组Gensini评分最高;C组入院时Gensini评分、CI术后1周LVWMSI、随访6个月再发心肌梗死、心力衰竭、心律失常发生率均显著高于A、B组,B组以上指标均明显高于A组(P0.05);Pearson相关性分析显示患者24 h血清BNP水平与LVWMSI呈显著正相关(r=0.728,P0.01)。结论:血清BNP水平可有效反映STEMI患者PCI术后心功能,对近期不良心血管事件有一定的预测价值。     

血浆IIA 分泌型磷脂酶A2 水平与冠脉支架术后再狭窄关系

目的:测定稳定型冠心病患者支架植入术(percutanous coronary intervention,PCI)前血浆IIA分泌型磷脂酶A2(group IIAsecretory phospholipase A2,ⅡA-sPLA2)的水平,以探讨该酶与冠脉支架术后再狭窄的可能关系。方法:稳定型冠心病行PCI患者63例,非冠心病患者39例,健康正常对照组42例,分别取外周静脉血测定血浆ⅡA-sPLA2酶浓度。PCI患者6个月后复查造影。结果:PCI患者术前该酶浓度显著高于正常对照组(P<0.05),支架内再狭窄率34.9%,再狭窄(restenosis,RS)患者支架术前该酶水平与无再狭窄患者该酶水平无统计学差异(P>0.05)。结论:PCI患者术前血浆ⅡA-sPLA2酶浓度显著高于正常对照组,但可能与支架术后再狭窄无关。     

伊伐布雷定对慢性心力衰竭患者血浆桥接整合因子1含量的影响

目的:探讨伊伐布雷定对慢性心力衰竭(chronic heart failure,CHF)患者血浆中桥接整合因子1(bridging integrator 1,Bin1)的影响。方法:收集左室射血分数(left ventricular ejection fraction,LVEF)小于40%的CHF患者40例,分为伊伐布雷定组20例,常规治疗组20例;选择23例同期体检且年龄、性别与实验组无统计学差异者作为对照组。入选对象采集清晨空腹静脉血,CHF患者于治疗30天后再次采集空腹静脉血。测定血浆Bin1和NT-proBNP浓度,心脏彩超检测LVEF、左室舒张末期内径(end-diastolic diameter of left ventricle,LVEDd)、E峰、A峰及E/A比值。结果:CHF患者血浆Bin1浓度(1047.85±304.82 pg/mL)较对照组(1248.84±238.04 pg/mL)显著降低,差异有统计学意义(P0.05)。CHF患者血浆Bin1浓度与LVEF呈正相关(r=0.567,P0.05),与LVEDd (r=-0.332,P0.05)、NT-proBNP呈负相关(r=-0.509,P0.05)。伊伐布雷定组治疗后Bin1浓度较治疗前升高(△234.98±267.18 pg/mL),常规治疗组治疗后Bin1浓度较治疗前升高(△34.87±66.89 pg/m L),伊伐布雷定组治疗前后血浆Bin1浓度变化常规治疗组更明显,差异具有统计学意义(P0.05)。结论:CHF患者血中Bin1浓度显著降低,与心功不全程度相关;伊伐布雷定可升高CHF患者血浆Bin1浓度,可能对改善衰竭心肌兴奋收缩耦联、提高心肌收缩力有益。     

血浆IIA分泌型磷脂酶A2水平与冠脉支架术后再狭窄关系

目的：测定稳定型冠心病患者支架植入术（percutanous coronary intervention,PCI）前血浆IIA分泌型磷脂酶A2（group IIA secretory phospholipase A2,IIA-sPLA2）的水平,以探讨该酶与冠脉支架术后再狭窄的可能关系。方法：稳定型冠心病行PCI患者63例,非冠心病患者39例,健康正常对照组42例,分别取外周静脉血测定血浆IIA-sPLA2酶浓度。PCI患者6个月后复查造影。结果：PCI患者术前该酶浓度显著高于正常对照组（P〈0．05）,支架内再狭窄率34．9％,再狭窄（restenosis,RS）患者支架术前该酶水平与无再狭窄患者该酶水平无统计学差异（P〉0．05）。结论：PCI患者术前血浆IIA-sPLA2酶浓度显著高于正常对照组,但可能与支架术后再狭窄无关。     

急性心肌梗死患者冠脉介入治疗后血浆apelin的变化及作用

目的:观察急性心肌梗死(AMI)患者围手术期血浆apelin的表达变化,分析AMI合并2型糖尿病(T2DM)患者血浆apelin的表达与预后的相关性,探讨apelin在冠脉介入治疗(PCI)中的心脏保护作用。方法:72例于2012年2月~8月在我院心内科接受冠状动脉造影确诊为AMI并成功完成PCI的冠心病患者,分别在术前、术后0小时、术后4小时、术后24小时收集血清,酶联免疫吸附法测定血浆apelin-13水平;进一步对糖尿病及非糖尿病AMI患者(每组各20例)进行亚组分析,随访两组患者在术后6个月时主要不良心脑血管事件(MACCE)。结果:AMI患者术后0 h组apelin水平与术前基线水平明显降低(31.54±5.48 vs35.15±6.48 ng/L,P0.05);术后4小时及24小时组apelin水平较术前明显升高(39.65±5.48 vs 35.15±6.48 ng/L,43.93±5.37 vs35.15±6.48 ng/L,P0.05)。糖尿病与非糖尿病组apelin水平术前无明显差异;糖尿病组在术后各时间点的apelin水平均明显高于非糖尿病组(31.12±5.50 vs 29.21±6.53 ng/L,40.57±5.37 vs 33.49±3.89 ng/L,43.50±7.41 vs 34.54±3.52 ng/L,P0.05)。两组术后6个月随访T2DM组LVEF值改善明显高于NT2DM组,但MACCE事件无明显差异。结论:AMI患者PCI术后存在血浆apelin表达的升高,其中糖尿病患者在术后血浆apelin表达较非糖尿病患者明显增高,提示PCI冠脉血运重建可促进糖尿病患者apelin分泌,调节胰岛素抵抗改善预后。     

TURBT术后即刻膀胱灌注不同浓度吡柔比星对浅表性膀胱癌患者免疫功能及生活质量的影响

目的:研究经尿道膀胱肿瘤电切术(TURBT)术后即刻膀胱灌注不同浓度吡柔比星对浅表性膀胱癌(SBC)患者免疫功能及生活质量的影响。方法:选择从2015年6月到2018年6月在我院治疗的SBC患者126例作为此次研究对象。依据随机数字法将患者分成观察组以及对照组,每组各63例,两组患者均常规给予TURBT治疗,手术完成后即刻,观察组患者采用30 mg的吡柔比星~+30 m L浓度为5%的葡萄糖液行胱灌注化疗,对照组采用30 mg的吡柔比星~+50 m L浓度为5%的葡萄糖液行胱灌注化疗。治疗1年后对比两组复发情况、免疫功能指标、生活质量以及不良反应。结果:观察组的复发率明显低于对照组,且复发时间明显长于对照组,差异均有统计学意义(P0.05)。两组治疗后的CD3~+、CD4~+、CD8~+水平及生活质量各方面评分均明显高于治疗前,差异有统计学意义(P0.05);两组治疗前及治疗后的CD3~+、CD4~+、CD8~+水平及生活质量各方面评分相比差异无统计学意义(P0.05)。观察组各种不良反应及其总发生率与对照组相比差异无统计学意义(P0.05)。结论:SBC患者在TURBT术后即刻实施吡柔比星膀胱灌注能够提升其免疫功能及生活质量,但30 mg的吡柔比星~+30 m L浓度为5%的葡萄糖液的膀胱灌注用药方案能够获得更低的术后复发率,复发时间也随之延长。     

心脏瓣膜病患者围手术期血浆BNP水平的表达及与心功能的关系

目的:通过探讨心脏瓣膜病患者围手术期血浆脑钠肽(BNP)水平的表达与心功能的关系,为相关治疗提供参考。方法:选择2014年10月~2015年10月本院收治的心脏瓣膜病患者共50例,分别于术前1 d、术后6 h、24 h、48 h和术后7 d测量患者血浆BNP水平,并观测患者左心射血分数(LVEF)、心功能分级、术后呼吸机辅助时间以及住院期间并发症发生情况。结果:术前不同心功能分级患者血浆BNP水平的总体差异有统计学意义(F=45.767,P0.05),心功能分级越高,血浆BNP水平越高;心脏功能IV级患者血浆BNP水平高于Ⅲ级,Ⅲ级患者血浆BNP水平高于II级(P0.05)。术后LVEF50%和LVEF≥50%患者,术前1 d血浆BNP水平分别为(724.21±132.16)pg/m L和(428.64±149.31)pg/m L,差异有统计学意义(t=6.628,P0.001)。不同时间点患者血浆BNP水平的总体差异有统计学意义(F=29.003,P0.001)。与术前比较,术后24 h、术后48 h和术后7 d时血浆BNP水平均显著升高(P0.05);术后48h时BNP浓度最高,随后开始下降。术后呼吸机辅助使用时间24 h和≥24 h的患者,术前1 d血浆BNP水平的差异有统计学意义(t=2.378,P=0.021)。结论:心脏瓣膜病患者围手术期血浆BNP水平的变化能够准确的反映患者心功能情况,对患者术前病情评估和术后临床处理具有一定的指导意义。`     

不同剂量ASA对PCI术后患者血浆TXB2和P选择素水平的影响

目的:经皮冠脉介入治疗(PCI)术后阿司匹林的剂量一直是人们争论的问题。虽然国外多个大型临床研究发现PCI术后服用低剂量阿司匹林(≤100 mg/d)较高剂量阿司匹林(300 mg/d)可同样预防缺血事件,而且还可以减少出血事件的发生,但这些研究均未对不同剂量阿司匹林抑制血小板聚集及活化情况进行检测,我们通过对PCI术后服用不同剂量阿司匹林患者血浆中血栓烷素B2(TXB2)和P选择素的水平的检测,为PCI术后阿司匹林合理剂量提供更有力的依据。方法:我们于2011年5月至2012年12月间,连续入选在我院行冠状动脉造影并置入了支架且符合入选标准的患者150例,随机分为低剂量阿司匹林组(PCI术后阿司匹林100 mg/d)和高剂量阿司匹林组(PCI术后阿司匹林300 mg/d服用3个月后改100 mg/d),采用酶联免疫吸附双抗体夹心法分别于服用阿司匹林前以及PCI术后5-7天检测血浆中TXB2、P选择素水平。结果:与服用阿司匹林前相比,服用阿司匹林后,各组血浆中TXB2和P选择素均有明显下降,PCI术后两组间血浆中TXB2和P选择素的水平均无显著差异。结论:PCI术后低剂量阿司匹林(≤100 mg/d)抑制血小板聚集及活化的效果与高剂量阿司匹林(300 mg/d)相同。     

儿童颅面部血管瘤及血管畸形的DSA诊断及介入治疗分析

探讨儿童颅面部血管瘤及血管畸形的数字减影血管造影(DSA)诊断及介入治疗效果。选取2014年2月至2016年12月在我院治疗的颅面部血管瘤及血管畸形儿童32例,采用DSA诊断,并采用经皮股动脉穿刺插管行双侧颈外动脉造影栓塞,观察治疗效果。采用选择性DSA诊断儿童颅面部血管瘤及血管畸形的准确率为100%;介入治疗即刻疗效和术后6个月疗效比较差异无统计学意义(p0.05),术后6个月显效和有效比例分别为75.00%和21.88%;不同性别、年龄患儿介入治疗术后6个月疗效比较差异无统计学意义(p0.05);患者治疗前及治疗后TNF-α和IL-6差异比较无统计学意义(p0.05);患者治疗后VEGF浓度为(102.01±37.10)pg/m L,明显较治疗前降低(p0.05)。DSA在儿童颅面部血管瘤及血管畸形诊断中有较好的应用价值,是一种可靠有效的诊断方法;介入治疗有较好的效果,值得临床推广使用。     

血流剪切力对支架内新生动脉粥样硬化形成的影响

目的:探讨血流剪切力对支架内新生粥样硬化斑块形成的影响。方法:在6只新西兰白兔右髂动脉植入金属裸支架,术后高脂喂养8周。将支架按长度均等分为近中远3段,应用多普勒超声测量各支架段血管的血流速度和血管内径,根据Poiseuille定律计算出术后即刻及术后8周时各支架段的平均血流剪切力。应用光学相干断层成像技术(optical coherence tomography,OCT)检测术后8周支架内新生内膜的生长情况及特性。结果:成功建立支架内斑块动物模型。术后即刻近中远支架段的血流剪切力分别为4.25±0.92,2.49±1.07,1.67±0.49Pa(P0.05);术后8周近中远支架段血流剪切力分别为20.40±6.07,11.09±1.74,7.97±0.26Pa(P0.05),均较术后即刻明显升高(P0.001);术后8周近中远支架段的内膜异质性发生率分别为86.67%,53.33%,41.12%(P0.05);术后8周近中远支架段OCT检测的富含脂质斑块的发生率分别为53.3%,20%,0%(P0.05)。结论:支架内新生粥样硬化斑块的发生可能与较高的血流剪切力相关。     

A Cultural History of Animals (6 Volumes)

ABSTRACT

Handling and training methods of horses, which specially emphasize the importance of understanding horse body language and the use of reinforcements, are often used in practice, yet their effects are not completely known. This study investigated whether the use of a sympathetic approach during the preparation for public auctions influenced the reactivity of young horses towards humans. Sixteen thoroughbred yearlings were prepared for the public auctions during one month: eight horses (“Control”) were handled according to conventional practices, while the others (“Treated”) were handled with two sessions of basic training based on body language. The reactivity of horses was assessed in the presence of an “unfamiliar person” and a “familiar person” inside the horse's box. The experimenter recorded the presence/absence of selected behaviors during seven observational moments: “approaching the box,” “opening the box door,” “entering the box,” and four consecutive observations every thirty seconds. Reactivity of horses was ranked during the first experience of “bit,” “grooming,” “shower,” and application of the “surcingle.” Heart rate was telemetrically recorded during this final test. At the end of the auction preparation, “Treated” horses exhibited more “contact” (p = 0.08) and “lick” (p < 0.05) behaviors in the presence of a person. “Control” horses showed higher (non-significant) percentages of negative (more nervous) rankings during “bit,” “grooming,” and “surcingle” tests. Two “Control” horses showed aggressive behavior during the application of the surcingle and the test was interrupted to guarantee person and animal safety. In this pilot study, horses handled with a sympathetic approach showed less reactive behaviors compared with “Control” horses. It would be interesting to enlarge the sample size and assess if the use of non-coercive handling during the whole training period influences their welfare positively and for a long time.     

Regulation of BECN1-mediated autophagy by HSPB6: Insights from a human HSPB6S10F mutant

HSPB6/Hsp20 (heat shock protein family B [small] member 6) has emerged as a novel cardioprotector against stress-induced injury. We identified a human mutant of HSPB6 (HSPB6^S10F) exclusively present in dilated cardiomyopathy (DCM) patients. Cardiac expression of this mutant in mouse hearts resulted in remodeling and dysfunction, which progressed to heart failure and early death. These detrimental effects were associated with reduced interaction of mutant HSPB6^S10F with BECN1/Beclin 1, leading to BECN1 ubiquitination and its proteosomal degradation. As a result, autophagy flux was substantially inhibited and apoptosis was increased in HSPB6^S10F-mutant hearts. In contrast, overexpression of wild-type HSPB6 (HSPB6 WT) not only increased BECN1 levels, but also competitively suppressed binding of BECN1 to BCL2, resulting in stimulated autophagy. Indeed, preinhibition of autophagy attenuated the cardioprotective effects of HSPB6 WT. Taken together, these findings reveal a new regulatory mechanism of HSPB6 in cell survival through its interaction with BECN1. Furthermore, Ser10 appears to be crucial for the protective effects of HSPB6 and transversion of this amino acid to Phe contributes to cardiomyopathy.     

血清白介素-6和白介素-10浓度的变化与冠心病

目的探讨白介素-6(IL-6)、白介素-10(IL-10)在冠心病心绞痛患者血中的变化规律。方法检测25例不稳定型心绞痛、23例稳定型心绞痛患者及22例正常对照者组血中IL6、IL-10浓度并进行比较。结果不稳定型心绞痛组、稳定型心绞痛组及正常对照组血中IL-6分别为(298.6±52.4)、(143.2±46.9)、(75.1±32.7)pg/m l;不稳定型心绞痛组分别高于稳定型心绞痛组及正常对照组,差异均有非常显著性(均为P<0.001)。不稳定型心绞痛组、稳定型心绞痛组及正常对照组血IL-10分别为(173.7±30.9)、(80.4±15.6)、(38.2±7.5)pg/m l,不稳定型心绞痛组分别高于稳定型心绞痛组及正常对照组(P<0.01)。结论冠心病患者血清IL-6、IL-10的浓度升高。     

冠心病患者血清白介素-6和C-反应蛋白的水平变化及临床意义

探讨白介素-6(IL-6)和C-反应蛋白(CRP)在冠心病(CHD)的发生发展中所起的作用及其之间的相互关系和临床意义。对70例住院冠心病患者采用ELISA和散射比浊法分别测定其血清中的IL-6、CRP水平的变化并与同期体检健康者34例作对照。显示患者CRP、IL-6值均明显高于对照组,差异显著(P<0.01)。炎症反应在冠心病的发生发展中起着重要的作用。如果能够在测定病人CRP及IL-6水平的同时建立患者的个体标准,则可以对患者病变程度及预后提供更好的临床依据。     

白细胞介素-10、白细胞介素-6对慢性肺源性心脏病预后评价的临床意义

目的:检测慢性肺源性心脏病患者血清白细胞介素-10和白细胞介素-6的水平,探讨细胞因子对慢性肺源性心脏病患者预后评价的临床意义。方法:将我院住院治疗的慢性肺源性心脏病患者40例,按照心功能情况分为肺源性心脏病组21例(对照组)和肺源性心脏病合并心力衰竭组19例(观察组),进行血清白介素-6、白介素-10定量检测。结果:观察组血清白介素-6水平较对照组明显升高,而白细胞介素-10却明显低于对照组(P值均<0.05)。结论:检测白细胞介素-6、白细胞介素-10的水平,可作为监测肺源性心脏病心功能恶化的预测指标。     

Protective effect of vitamin B6 against doxorubicin-induced cardiotoxicity by modulating NHE1 expression

Doxorubicin (DOX) has been used to treat various types of cancer, but its application is limited due to its heart toxicity as well as other drawbacks. Chronic inhibition of Na⁺/H⁺ exchanger (NHE1) reduces heart failure and reduces the production of reactive oxygen species (ROS); vitamin B6 (VitB₆) has been demonstrated to have a crucial role in antioxidant mechanism. So, this study was designed to explore the effect of VitB₆ supplement on the DOX-induced cardiotoxicity and to imply whether NHE1 is involved. Ultrasonic cardiogram analysis revealed that VitB₆ supplement could alleviate DOX-induced cardiotoxicity; hematoxylin and eosin (HE) and Masson's staining further confirmed this effect. Furthermore, VitB₆ supplement exhibited significant antioxidative stress and antiapoptosis effect, which was evidenced by decreased serum malondialdehyde (MDA) content and increased serum superoxide dismutase (SOD) content, and decreased Bcl-2-associated X protein/B-cell lymphoma-2 ratio, respectively. Collectively, VitB₆ supplement may exert antioxidative and antiapoptosis effects to improve cardiac function by decreasing NHE1 expression and improve DOX-induced cardiotoxicity.     

Oxygen Radical Injury and Loss of High-Energy Compounds in Anoxic and Reperfused Rat Heart: Prevention By Exogenous Fructose-1, 6-Bisphosphate

Isolated Langendorff-perfused rat hearts after 10 minutes preperfusion, were subjected to a substrate-free anoxic perfusion (20 minutes) followed by 20 minutes reperfusion with a glucose-containing oxygen-balanced medium. Under the same perfusion conditions, the effect of exogenous 5mM fructose-1, 6-bisphosphate has been investigated. The xanthine dehydrogenase to xanthine oxidase ratio, concentrations of high-energy phosphates and the TBA-reactive material (TBARS) were determined at the end of each perfusion period in both control and fructose-1, 6-bisphosphate-treated hearts. Results indicate that anoxia induces the irreversible transformation of xanthine dehydrogenase into oxidase as a consequence of the sharp decrease of the myocardial energy metabolism. This finding is supported by the protective effect exerted by exogenous fructose-1, 6-bisphosphate which is able to maintain the correct xanthine dehydrogenase/oxidase ratio by preventing the depletion of phosphorylated compounds during anoxia. Moreover, in control hearts, the release oflactate dehydrogenase during reperfusion, is paralleled by a 50% increase in the concentration of tissue TBARS. On the contrary, in fructose-1, 6-bisphosphate-treated hearts this concentration does not significantly change after reoxygenation, while a slight but significant increase of lactate dehydrogenase activity in the perfusates is observed.

On the whole these data indicate a direct contribution of oxygen-derived free radicals to the worsening of post-anoxic hearts. A hypothesis on the mechanism of action of fructose-1, 6-bisphosphate in anoxic and reperfused rat heart and its possible application in the clinical therapy of myocardial infarction are presented.     

Physiological relevance of the changing subunit composition and regulatory properties of the 6-phosphofructo-1-kinase isozyme pools during heart and muscle development

During postnatal development, the subunit compositions of the 6-phosphofructo-l-kinase isozyme pools of heart and skeletal muscle are known to change. The isozyme pools from fetal muscle were composed of the L-type (60%), and M-type (36%) and C-type (4%) subunits and the isozymes from fetal and early neonatal heart contain nearly equal amounts of all three subunits. During postnatal development of both tissues, the proportion of the M-type subunit increases until it is the only type present in adult muscle and the major subunit in adult heart (7507o). The isozyme pool from fetal muscle exhibit a decreased affinity for fructose-6-P and a greater susceptibility to ATP inhibition compared to the M-rich isozymes which are subsequently present. The isozyme pools from fetal and early neonatal heart, if compared to the M-rich isozymes which are present later during heart development and to the fetal muscle isozymes, exhibited the least affinity for fructose-6-P and the greatest susceptibility to ATP inhibition. Comparison of the isozyme pools containing little or no C-type subunit with those from fetal and early neonatal heart clearly indicates that the presence of substantial levels of the C-type subunit imposed a decreased ability for fructose-2,6-P₂ to both lower affinity for fructose-6-P and antagonize sensitivity to ATP inhibition. Although still not thoroughly appreciated, it appears that the changing nature of the isozyme pools in these tissues permits regulation of glucose metabolism in a manner which allows efficient utilization of nutritional opportunities and which adequately meets the energy requirements of each tissue at different stages of development.Abbreviations PFK 6-phosphofructo-l-kinase - fructose-6-P D-fructose-6-phosphate - fr-t_ose-2,6-P₂ D-fructose-2,6-bisphosphate     

氯吡格雷联合阿司匹林对冠心病心绞痛患者血清hs-CRP, TNF-alpha 及IL-6 水平的影响

目的：探讨氯吡格雷与阿司匹林对冠心病心绞痛患者血清炎症因子水平的影响及其临床疗效。方法：选择2014 年3月-2016 年3 月在我院确诊为冠心病心绞痛患者69 例作为研究对象,根据治疗方法不同,将患者随机分成研究组（39 例）和对照组（30 例）。对照组患者采用阿司匹林治疗,研究组患者在此基础上联合使用氯吡格雷治疗。观察并比较两组患者治疗前后血清高敏C- 反应蛋白(high-sensitivity C-reactive protein, hs-CRP)、肿瘤坏死因子-alpha（tumor necrosis factor-alpha, TNF-alpha）及白细胞介素-6 (interleukin-6, IL-6)水平的变化情况,以及临床疗效。结果：治疗前两组患者血清hs-CRP,IL-6 及TNF-alpha水平比较,差异无统计学 意义（P>0.05）;治疗后两组患者血清hs-CRP,IL-6 及TNF-alpha水平均低于治疗前,且研究组低于对照组,差异具有统计学意义（P<0. 05）。研究组患者临床总有效率（94.7%）高于对照组（88.9%）,差异具有统计学意义（P<0.05）。结论：氯吡格雷联合阿司匹林治疗冠 心病心绞痛的临床效果显著,能够降低患者血清hs-CRP,IL-6 及TNF-alpha炎症因子水平,值得临床推广应用。